FDA alerts clinicians about fake Botox

January 9, 2013

Washington - Unapproved versions of onabotulinumtoxinA (Botox, Allergan) sent by foreign suppliers has prompted the Food and Drug Administration to issue alerts to more than 350 medical practices that may have purchased the products.

Washington - Unapproved versions of onabotulinumtoxinA (Botox, Allergan) sent by foreign suppliers has prompted the Food and Drug Administration to issue alerts to more than 350 medical practices that may have purchased the products.

Distributors owned by Canada Drugs may have sent the unapproved neurotoxin products to practices in the U.S., Medical News Today reports. Suppliers owned by Canada Drugs include Bridgewater Medical, Clinical Care, A+ Health Supplies and QSP.

Some of the products these distributors sell have not been reviewed and approved by the FDA, and thus the agency can’t confirm that the manufacture or handling of the medications and neurotoxins are safe. The unapproved neurotoxins could be contaminated, unsafe or ineffective, the FDA warned.